Recent News

• 07.28.2026 - BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
• 06.02.2026 - BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
• 05.28.2026 - BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
• 05.19.2026 - BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
• 05.15.2026 - BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
• 03.31.2026 - BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
• 02.26.2026 - Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
• 02.20.2026 - Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
• 11.14.2025 - BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
• 08.14.2025 - BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 07.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 3 Initial statement of beneficial ownership of securities
• 06.02.2026 - EFFECT Notice of Effectiveness
• 05.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - 8-K Current report